Therefore, further studies are warranted to better understand the role of the EGFR/PAK1 pathway for improving the survival rates in patients with EGFR-mutated NSCLC, even after they have acquired resistance to tyrosine kinase inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.